Association Between Use of Sodium-Glucose Cotransporter-2 Inhibitors or Angiotensin Receptor-Neprilysin Inhibitor and the Risk of Atherosclerotic Cardiovascular Disease With Coexisting Diabetes and Heart Failure

• Main Authors: Ya-Wen Lin PhD, RN (Author), Chun-Hsiang Lin MS, MD (Author), Cheng-Li Lin MS (Author), Che-Huei Lin PhD, BPhar (Author), Ming-Hung Lin PhD, BPhar (Author)
• Formato: Livro
• Publicado em: SAGE Publishing, 2024-02-01T00:00:00Z.
• Assuntos: article
• Acesso em linha: Connect to this object online.

Purpose This study was to investigate the association between the use of Sodium-glucose Cotransporter-2 inhibitors (SGLT2i) or angiotensin receptor-neprilysin inhibitor (ARNI; ie, Sacubitril + valsartan, Product name ENTRESTO) and the risk of atherosclerotic cardiovascular disease (ASCVD) in patient...